Table of Contents
Advances in Geriatrics
Volume 2014, Article ID 302712, 14 pages
http://dx.doi.org/10.1155/2014/302712
Review Article

CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design

Department of Neurology, Knight Alzheimer’s Disease Research Center, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA

Received 13 April 2014; Revised 30 June 2014; Accepted 1 July 2014; Published 14 August 2014

Academic Editor: Stephen D. Ginsberg

Copyright © 2014 Anne M. Fagan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. D. James, S. E. Leurgans, L. E. Hebert et al., “Contribution of Alzheimer disease to mortality in the United States,” Neurology, vol. 82, pp. 1045–1050, 2014. View at Google Scholar
  2. S. S. Mirra, A. Heyman, D. McKeel et al., “The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease,” Neurology, vol. 41, no. 4, pp. 479–486, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. S. Khachaturian, “Diagnosis of Alzheimer's disease,” Archives of Neurology, vol. 42, no. 11, pp. 1097–1105, 1985. View at Publisher · View at Google Scholar · View at Scopus
  4. B. T. Hyman and J. Q. Trojanowski, “Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease,” Journal of neuropathology and experimental neurology, vol. 56, no. 10, pp. 1095–1097, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. T. J. Montine, C. H. Phelps, T. G. Beach et al., “National institute on aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach,” Acta Neuropathologica, vol. 123, no. 1, pp. 1–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Holtzman, J. C. Morris, and A. M. Goate, “Alzheimer's disease: the challenge of the second century,” Science Translational Medicine, vol. 3, no. 77, Article ID 77sr1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. G. McKhann, D. Drachman, and M. Folstein, “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease,” Neurology, vol. 34, no. 7, pp. 939–944, 1984. View at Publisher · View at Google Scholar · View at Scopus
  8. T. G. Beach, S. E. Monsell, L. E. Phillips, and W. Kukull, “Accuracy of the clinical diagnosis of Alzheimer disease at national institute on aging Alzheimer disease centers, 2005–2010,” Journal of Neuropathology and Experimental Neurology, vol. 71, no. 4, pp. 266–273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Handels, P. Aalten, C. A. Wolfs et al., “Diagnostic and economic evaluation of new biomarkers for Alzheimers disease: the research protocol of a prospective cohort study,” BMC Neurology, vol. 12, p. 72, 2012. View at Google Scholar
  10. J. L. Cummings and D. V. Jeste, “Alzheimer's disease and its management in the year 2010,” Psychiatric Services, vol. 50, no. 9, pp. 1173–1177, 1999. View at Google Scholar · View at Scopus
  11. C. S. Teel, “Rural practitioners' experiences in dementia diagnosis and treatment,” Aging and Mental Health, vol. 8, no. 5, pp. 422–429, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Hassenstab, J. Burns, and J. Morris, “Clinical and neuropsychological features of Alzheimer's disease,” in Neurobiology of Mental Illness, D. Charney and E. J. Nestler, Eds., pp. 791–804, Oxford University Press, Oxford, UK, 4th edition, 2013. View at Google Scholar
  13. B. Dubois, H. H. Feldman, C. Jacova et al., “Revising the definition of Alzheimer's disease: a new lexicon,” Lancet Neurology, vol. 9, no. 11, pp. 1118–1127, 2010. View at Google Scholar
  14. G. M. McKhann, D. S. Knopman, H. Chertkow et al., “The diagnosis of dementia due to Alzheimers disease: Recommendations from the National Institute on Aging and the Alzheimers Association Workgroup,” Alzheimer's & Dementia, vol. 7, pp. 263–269, 2011. View at Google Scholar
  15. M. Albert, S. T. DeKosky, and D. Dickson, “The diagnosis of Mild Cognitive Impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association Workgroup,” Alzheimer's & Dementia, vol. 7, no. 3, pp. 270–279, 2011. View at Google Scholar
  16. R. A. Sperling, P. S. Aisen, L. A. Beckett et al., “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's & Dementia, vol. 7, no. 3, pp. 280–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Morris, K. Blennow, L. Froelich et al., “Harmonized diagnostic criteria for Alzheimer's disease: recommendations,” Journal of Internal Medicine, vol. 275, pp. 204–213, 2014. View at Publisher · View at Google Scholar
  18. K. Blennow, “Biomarkers in Alzheimer's disease drug development,” Nature Medicine, vol. 16, no. 11, pp. 1218–1222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. T. Vilming, H. Schrader, and I. Monstad, “The significance of age, sex, and cerebrospinal fluid pressure in post-lumbar-puncture headache,” Cephalalgia, vol. 9, no. 2, pp. 99–106, 1989. View at Publisher · View at Google Scholar · View at Scopus
  20. S. V. Ahmed, C. Jayawarna, and E. Jude, “Post lumbar puncture headache: diagnosis and management,” Postgraduate Medical Journal, vol. 82, no. 973, pp. 713–716, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Blennow, A. Wallin, and O. Häger, “Low frequency of post-lumbar puncture headache in demented patients,” Acta Neurologica Scandinavica, vol. 88, no. 3, pp. 221–223, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. E. R. Peskind, R. Riekse, J. F. Quinn et al., “Safety and acceptability of the research lumbar puncture,” Alzheimer Disease and Associated Disorders, vol. 19, no. 4, pp. 220–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Peskind, A. Nordberg, T. Darreh-Shori, and H. Soininen, “Safety of lumbar puncture procedures in patients with Alzheimer's disease,” Current Alzheimer Research, vol. 6, no. 3, pp. 290–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Strozyk, K. Blennow, L. R. White, and L. J. Launer, “CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study,” Neurology, vol. 60, no. 4, pp. 652–656, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Tapiola, I. Alafuzoff, S. Herukka et al., “Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain,” Archives of Neurology, vol. 66, no. 3, pp. 382–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. M. Clark, S. Xie, J. Chittams et al., “Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?” Archives of Neurology, vol. 60, no. 12, pp. 1696–1702, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Fagan, M. A. Mintun, R. H. Mach et al., “Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans,” Annals of Neurology, vol. 59, no. 3, pp. 512–519, 2006. View at Publisher · View at Google Scholar
  28. A. Forsberg, H. Engler, O. Almkvist et al., “PET imaging of amyloid deposition in patients with mild cognitive impairment,” Neurobiology of Aging, vol. 29, no. 10, pp. 1456–1465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Grimmer, M. Riemenschneider, H. Förstl et al., “Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid,” Biological Psychiatry, vol. 65, no. 11, pp. 927–934, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Tolboom, W. M. van der Flier, M. Yaqub et al., “Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding,” Journal of Nuclear Medicine, vol. 50, no. 9, pp. 1464–1470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. W. J. Jagust, S. M. Landau, L. M. Shaw et al., “Relationships between biomarkers in aging and dementia,” Neurology, vol. 73, no. 15, pp. 1193–1199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Hong, O. Quintero-Monzon, B. L. Ostaszewski et al., “Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in isf versus parenchymal Aβ during age-related plaque formation,” Journal of Neuroscience, vol. 31, no. 44, pp. 15861–15869, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. M. Fagan, M. A. Mintun, A. R. Shah et al., “Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease,” EMBO Molecular Medicine, vol. 1, no. 8-9, pp. 371–380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Irwin, J. Trojanowski, and M. Grossman, “Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease,” Frontiers in Aging Neuroscience, vol. 5, no. 6, 2013. View at Publisher · View at Google Scholar
  35. C. Yao, A. J. Williams, A. K. Ottens et al., “Detection of protein biomarkers using high-throughput immunoblotting following focal ischemic or penetrating ballistic-like brain injuries in rats,” Brain Injury, vol. 22, no. 10, pp. 723–732, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Öst, K. Nylén, L. Csajbok et al., “Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury,” Neurology, vol. 67, no. 9, pp. 1600–1604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Blennow, “Cerebrospinal fluid protein biomarkers for Alzheimer's disease,” NeuroRx, vol. 1, no. 2, pp. 213–225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Otto, J. Wiltfang, H. Tumani et al., “Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease,” Neuroscience Letters, vol. 225, no. 3, pp. 210–212, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. M. B. Coulthart, G. H. Jansen, E. Olsen et al., “Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study,” BMC Neurology, vol. 11, article 133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Skillbäck, C. Rosén, F. Asztely, N. Mattsson, K. Blennow, and H. Zetterberg, “Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry,” JAMA Neurology, vol. 71, no. 4, pp. 476–483, 2014. View at Publisher · View at Google Scholar
  41. N. Kfoury, B. B. Holmes, H. Jiang, D. M. Holtzman, and M. I. Diamond, “Trans-cellular propagation of Tau aggregation by fibrillar species,” The Journal of Biological Chemistry, vol. 287, no. 23, pp. 19440–19451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Yamada, J. R. Cirrito, F. R. Stewart et al., “In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice,” Journal of Neuroscience, vol. 31, no. 37, pp. 13110–13117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Yamada, J. K. Holth, F. Liao et al., “Neuronal activity regulates extracellular tau in vivo,” The Journal of Experimental Medicine, vol. 211, no. 3, pp. 387–393, 2014. View at Google Scholar
  44. H. Hampel, K. Blennow, L. M. Shaw, Y. C. Hoessler, H. Zetterberg, and J. Q. Trojanowski, “Total and phosphorylated tau protein as biological markers of Alzheimer's disease,” Experimental Gerontology, vol. 45, no. 1, pp. 30–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Buerger, M. Ewers, T. Pirttilä et al., “CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease,” Brain, vol. 129, no. 11, pp. 3035–3041, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Chien, A. K. Szardenings, S. Bahri et al., “Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808,” Journal of Alzheimer's Disease, vol. 38, no. 1, pp. 171–184, 2014. View at Publisher · View at Google Scholar
  47. A. M. Fagan and R. J. Perrin, “Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease,” Biomarkers in Medicine, vol. 6, no. 4, pp. 455–476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Lee, K. Blennow, N. Andreasen et al., “The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients,” Clinical Chemistry, vol. 54, no. 10, pp. 1617–1623, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Craig-Schapiro, R. J. Perrin, C. M. Roe et al., “YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease,” Biological Psychiatry, vol. 68, pp. 903–912, 2010. View at Google Scholar
  50. R. Tarawneh, G. D'Angelo, E. MacY et al., “Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease,” Annals of Neurology, vol. 70, no. 2, pp. 274–285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. R. J. Perrin, R. Craig-Schapiro, J. P. Malone et al., “Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease,” PLoS ONE, vol. 6, no. 1, Article ID e16032, 2011. View at Google Scholar · View at Scopus
  52. B. Olsson, J. Hertze, R. Lautner et al., “Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia,” Journal of Alzheimer's Disease, vol. 33, no. 1, pp. 45–53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. X. Luo, L. Hou, H. Shi et al., “CSF levels of the neuronal injury biomarker visinin-like protein-1 in alzheimer's disease and dementia with lewy bodies,” Journal of Neurochemistry, vol. 127, no. 5, pp. 681–690, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Tarawneh, J.-M. Lee, J. H. Ladenson, J. C. Morris, and D. M. Holtzman, “CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease,” Neurology, vol. 78, no. 10, pp. 709–719, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010. View at Publisher · View at Google Scholar
  56. C. M. Hulette, K. A. Welsh-Bohmer, M. G. Murray, A. M. Saunders, D. C. Mash, and L. M. McIntyre, “Neuropathological and neurolasychological changes in “normal” aging: evidence for preclinical Alzheimer Disease in cognitively normal individuals,” Journal of Neuropathology and Experimental Neurology, vol. 57, no. 12, pp. 1168–1174, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. J. L. Price and J. C. Morris, “Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease,” Annals of Neurology, vol. 45, pp. 358–368, 1999. View at Google Scholar
  58. D. Galasko, L. Chang, R. Motter et al., “High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer 's disease and relation to apolipoprotein E genotype,” Archives of Neurology, vol. 55, no. 7, pp. 937–945, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Maddalena, A. Papassotiropoulos, B. Müller-Tillmanns et al., “Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42,” Archives of Neurology, vol. 60, no. 9, pp. 1202–1206, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. G. M. Halliday, J. L. Holton, T. Revesz, and D. W. Dickson, “Neuropathology underlying clinical variability in patients with synucleinopathies,” Acta Neuropathologica, vol. 122, no. 2, pp. 187–204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. N. S. M. Schoonenboom, F. E. Reesink, N. A. Verwey et al., “Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort,” Neurology, vol. 78, no. 1, pp. 47–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G. Tangalos, and E. Kokmen, “Mild cognitive impairment: clinical characterization and outcome,” Archives of Neurology, vol. 56, pp. 303–308, 1999. View at Google Scholar
  63. R. C. Petersen, “Mild cognitive impairment as a diagnostic entity,” Journal of Internal Medicine, vol. 256, no. 3, pp. 183–194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Weiner, D. P. Veitch, P. S. Aisen et al., “The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception,” Alzheimer's & Dementia, vol. 9, no. 5, pp. e111–e194, 2013. View at Publisher · View at Google Scholar
  65. L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka et al., “Cerebrospinal fluid biomarker signature in alzheimer's disease neuroimaging initiative subjects,” Annals of Neurology, vol. 65, no. 4, pp. 403–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. C. C. Rowe, S. Ng, U. Ackermann et al., “Imaging β-amyloid burden in aging and dementia,” Neurology, vol. 68, no. 20, pp. 1718–1725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. P. J. Visser, F. Verhey, D. L. Knol et al., “Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study,” The Lancet Neurology, vol. 8, no. 7, pp. 619–627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Buchhave, L. Minthon, H. Zetterberg, Å. K. Wallin, K. Blennow, and O. Hansson, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia,” Archives of General Psychiatry, vol. 69, no. 1, pp. 98–106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. B. J. Snider, A. M. Fagan, C. Roe et al., “Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type,” Archives of Neurology, vol. 66, no. 5, pp. 638–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Braak and E. Braak, “Frequency of stages of Alzheimer-related lesions in different age categories,” Neurobiology of Aging, vol. 18, no. 4, pp. 351–357, 1997. View at Publisher · View at Google Scholar · View at Scopus
  72. J. L. Price, D. W. McKeel Jr., V. D. Buckles et al., “Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease,” Neurobiology of Aging, vol. 30, no. 7, pp. 1026–1036, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Vos, C. Xiong, P. J. Visser et al., “Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study,” The Lancet Neurology, vol. 12, no. 10, pp. 957–965, 2013. View at Publisher · View at Google Scholar
  74. C. R. Jack Jr., D. S. Knopman, S. D. Weigand et al., “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease,” Annals of Neurology, vol. 71, no. 6, pp. 765–775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. I. Skoog, P. Davidsson, Ó. Aevarsson, H. Vanderstichele, E. Vanmechelen, and K. Blennow, “Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds,” Dementia and Geriatric Cognitive Disorders, vol. 15, no. 3, pp. 169–176, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. D. R. Gustafson, I. Skoog, L. Rosengren, H. Zetterberg, and K. Blennow, “Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 5, pp. 461–464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Stomrud, O. Hansson, K. Blennow, L. Minthon, and E. Londos, “Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly,” Dementia and Geriatric Cognitive Disorders, vol. 24, no. 2, pp. 118–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman, “Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults,” Archives of Neurology, vol. 64, no. 3, pp. 343–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. G. Li, I. Sokal, J. F. Quinn et al., “CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study,” Neurology, vol. 69, no. 7, pp. 631–639, 2007. View at Google Scholar
  80. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study,” The Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. K. G. Mawuenyega, W. Sigurdson, V. Ovod et al., “Decreased clearance of CNS β-amyloid in Alzheimer's disease,” Science, vol. 330, no. 6012, p. 1774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. R. J. Bateman, P. S. Aisen, B. de Strooper et al., “Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease,” Alzheimer's Research and Therapy, vol. 2, no. 6, article 35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Moonis, J. M. Swearer, M. P. E. Dayaw et al., “Familial Alzheimer disease: decreases in CSF Aβ42 levels precede cognitive decline,” Neurology, vol. 65, no. 2, pp. 323–325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Bateman, C. Xiong, T. L. S. Benzinger et al., “Clinical and biomarker changes in dominantly inherited Alzheimer's disease,” The New England Journal of Medicine, vol. 367, pp. 795–804, 2012. View at Google Scholar
  85. A. Fagan, “Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer disease,” Science Translational Medicine, vol. 6, no. 226, p. 226ra30, 2014. View at Google Scholar
  86. T. Tapiola, H. Soininen, and T. Pirttilä, “CSF tau and Aβ42 levels in patients with Down's syndrome,” Neurology, vol. 56, no. 7, pp. 979–980, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. J. M. Ringman, S. G. Younkin, D. Pratico et al., “Biochemical markers in persons with preclinical familial Alzheimer disease,” Neurology, vol. 71, no. 2, pp. 85–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. C. R. Jack, D. S. Knopman, W. J. Jagust et al., “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers,” The Lancet Neurology, vol. 12, no. 2, pp. 207–216, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. R. J. Perrin, A. M. Fagan, and D. M. Holtzman, “Multimodal techniques for diagnosis and prognosis of Alzheimer's disease,” Nature, vol. 461, no. 7266, pp. 916–922, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. C. R. Jack Jr., D. S. Knopman, W. J. Jagust et al., “Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade,” The Lancet Neurology, vol. 9, no. 1, pp. 119–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. R. S. Desikan, L. K. McEvoy, W. K. Thompson et al., “Amyloid-β—associated clinical decline occurs only in the presence of elevated P-tau.,” Archives of Neurology, vol. 69, no. 6, pp. 709–713, 2012. View at Google Scholar · View at Scopus
  92. M. I. Kester, A. E. Van Der Vlies, M. A. Blankenstein et al., “CSF biomarkers predict rate of cognitive decline in Alzheimer disease,” Neurology, vol. 73, no. 17, pp. 1353–1358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. I. A. van Rossum, S. J. B. Vos, L. Burns et al., “Injury markers predict time to dementia in subjects with MCI and amyloid pathology,” Neurology, vol. 79, no. 17, pp. 1809–1816, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. K. Blennow, H. Zetterberg, L. Minthon et al., “Longitudinal stability of CSF biomarkers in Alzheimer's disease,” Neuroscience Letters, vol. 419, no. 1, pp. 18–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Zetterberg, M. Pedersen, K. Lind et al., “Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years,” Journal of Alzheimer's Disease, vol. 12, no. 3, pp. 255–260, 2007. View at Google Scholar · View at Scopus
  96. L. A. Beckett, D. J. Harvey, A. Gamst et al., “The Alzheimer's Disease neuroimaging initiative: annual change in biomarkers and clinical outcomes,” Alzheimer's and Dementia, vol. 6, no. 3, pp. 257–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. P. Vemuri, H. J. Wiste, S. D. Weigand et al., “Serial MRI and CSF biomarkers in normal aging, MCI, and AD,” Neurology, vol. 75, no. 2, pp. 143–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Kanai, E. Matsubara, K. Isoe et al., “Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan,” Annals of Neurology, vol. 44, pp. 17–26, 1998. View at Google Scholar
  99. T. Sunderland, B. Wolozin, D. Galasko et al., “Longitudinal stability of CSF tau levels in Alzheimer patients,” Biological Psychiatry, vol. 46, no. 6, pp. 750–755, 1999. View at Publisher · View at Google Scholar · View at Scopus
  100. J. B. Toledo, S. X. Xie, J. Q. Trojanowski, and L. M. Shaw, “Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI,” Acta Neuropathologica, vol. 126, pp. 659–670, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. C. R. Jack, M. S. Albert, D. S. Knopman et al., “Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's & Dementia, vol. 7, no. 3, pp. 257–262, 2011. View at Google Scholar
  102. M. I. Kester, L. Boelaarts, F. H. Bouwman et al., “Diagnostic impact of CSF biomarkers in a local hospital memory clinic,” Dementia and Geriatric Cognitive Disorders, vol. 29, no. 6, pp. 491–497, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. F. Mouton-Liger, D. Wallon, A. C. Troussière et al., “Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study,” Journal of Neurology, vol. 261, no. 1, pp. 144–151, 2014. View at Publisher · View at Google Scholar
  104. A. Troussière, D. Wallon, F. Mouton-Liger et al., “Who needs cerebrospinal biomarkers? A national survey in clinical practice,” Journal of Alzheimer's Disease, vol. 40, pp. 857–861, 2014. View at Google Scholar
  105. D. S. Knopman, C. R. Jack Jr., H. J. Wiste et al., “Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease,” Neurology, vol. 78, no. 20, pp. 1576–1582, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. J. C. Morris and D. J. Selkoe, “Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview,” Neurobiology of Aging, vol. 32, supplement 1, pp. S1–S3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. R. A. Sperling, C. R. Jack Jr., and P. S. Aisen, “Testing the right target and right drug at the right stage,” Science Translational Medicine, vol. 3, no. 111, Article ID 111cm33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Langbaum, A. S. Fleisher, K. Chen et al., “Ushering in the study and treatment of preclinical Alzheimer disease,” Nature Reviews Neurology, vol. 9, no. 7, pp. 371–381, 2013. View at Publisher · View at Google Scholar
  109. R. Sperling, D. M. Rentz, K. A. Johnson et al., “The A4 study: stopping AD before symptoms begin?” Science Translational Medicine, vol. 6, no. 228, p. 228fs13, 2014. View at Publisher · View at Google Scholar
  110. E. M. Reiman, J. B. S. Langbaum, A. S. Fleisher et al., “Alzheimers prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments,” Journal of Alzheimer's Disease, vol. 26, supplement 3, no. 3, pp. 321–329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Mills, J. Mallmann, A. M. Santacruz et al., “Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial,” Revue Neurologique, vol. 169, no. 10, pp. 737–743, 2013. View at Publisher · View at Google Scholar
  112. N. Mattsson, U. Andreasson, S. Persson et al., “The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers,” Alzheimer's and Dementia, vol. 7, no. 4, pp. 386.e6–395.e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. N. Mattsson, U. Andreasson, S. Persson et al., “CSF biomarker variability in the Alzheimer's association quality control program,” Alzheimer's and Dementia, vol. 9, no. 3, pp. 251–261, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. H. M. Vanderstichele, L. Shaw, M. Vandijck et al., “Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard,” Clinical Chemistry, vol. 59, no. 4, pp. 710–712, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. M. T. Fodero-Tavoletti, S. Furumoto, L. Taylor et al., “Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non Alzheimer's disease tauopathies,” Alzheimer's Research & Therapy, vol. 6, no. 1, p. 11, 2014. View at Google Scholar
  116. P. Giannetti, M. Politis, P. Su et al., “Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study,” Neurobiology of Disease, vol. 65, pp. 203–210, 2014. View at Publisher · View at Google Scholar
  117. J. W. Bartlett, C. Frost, N. Mattsson et al., “Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges,” Biomarkers in Medicine, vol. 6, no. 4, pp. 391–400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Luo and C. Xiong, “Youden index and associated cut-points for three ordinal diagnostic groups,” Communications in Statistics. Simulation and Computation, vol. 42, no. 6, pp. 1213–1234, 2013. View at Publisher · View at Google Scholar · View at Zentralblatt MATH · View at MathSciNet · View at Scopus
  119. S. Vos, I. van Rossum, L. Burns et al., “Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI,” Neurobiology of Aging, vol. 33, no. 10, pp. 2272–2281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. C. Xiong, G. van Belle, K. Chen et al., “Combining multiple markers to improve the longitudinal rate of progression—application to clinical trials on the early stage of Alzheimer's disease,” Statistics in Biopharmaceutical Research, vol. 5, no. 1, 2013. View at Google Scholar
  121. C. Bazenet and S. Lovestone, “Plasma biomarkers for Alzheimers disease: much needed but tough to find,” Biomarkers in Medicine, vol. 6, no. 4, pp. 441–454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. D. Alcolea, P. Martínez-Lage, A. Izagirre et al., “Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain,” Journal of Alzheimer's Disease, vol. 39, pp. 719–726, 2014. View at Publisher · View at Google Scholar
  123. H. Vanderstichele, M. Bibl, S. Engelborghs et al., “Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative,” Alzheimer's and Dementia, vol. 8, no. 1, pp. 65–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Karlawish, “Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease,” Neurology, vol. 77, no. 15, pp. 1487–1493, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Pearson, D. A. Ollendorf, J. A. Colby et al., “Biomarker tests for the diagnosis of Alzheimer's disease: generating evidence to inform insurance coverage determinations,” Alzheimer's & Dementia, vol. 9, no. 7, pp. 745–752, 2013. View at Publisher · View at Google Scholar